BeOne Medicines (ONC) Net Equity Issued and Repurchased (2020 - 2021)
BeOne Medicines (ONC) posted quarterly Net Equity Issued and Repurchased of $50000.0 for Q3 2021, down 100.0% year-over-year from $2.1 billion in Q3 2020, and down 100.0% quarter-over-quarter from $2.1 billion in Q3 2020.
Powered by 
Analysis
BeOne Medicines (ONC) Net Equity Issued and Repurchased (2020 - 2021) Analysis & Trends
BeOne Medicines (ONC) has reported Net Equity Issued and Repurchased for 2 consecutive years, with $50000.0 the latest figure, recorded in Q3 2021.
- In Q3 2021, Net Equity Issued and Repurchased fell 100.0% year-over-year to $50000.0; the TTM figure through Dec 2022 stood at $50000.0 (changed 0.0% YoY), while the FY2021 annual figure was $50.0 million, down 98.82% from the prior year.
- Net Equity Issued and Repurchased fell to $50000.0 in Q3 2021 per ONC's latest filing, from $2.1 billion in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $2.2 billion in Q1 2020 and bottomed at $50000.0 in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 50,000.00 |
| Sep 30, 2020 | 2.07 Bn |
| Mar 31, 2020 | 2.16 Bn |